Health Innovators

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic research at UK company Adaptimmune which is transforming cancer immunotherapy with affinity enhanced T-cell receptors.

Adaptimmune's SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. Jo discusses how Adaptimmune is taking its clinical pipeline to market and the challenges of developing cell therapies. She also shares her story in academia and industry, and her hopes for the future of cancer treatment.

About the author

Dr Paul Tunnah is Chief Content Officer and UK Managing Director for Healthware Group, a next-generation integrated consulting group that operates at the intersection of the transformation of commercial operations and digital health, offering a unique range of services combining design, strategy, communication and innovation with technology and corporate venturing.

Prior to this, he founded pharmaphorum in 2009, which was acquired by Healthware Group in June 2020. He is a recognised author, speaker and industry advisor with a passion for helping organisations tell authentic stories that resonate, co-create solutions and unlock the power of digital and social media in connecting with customers and understanding markets. Dr Tunnah holds a BA in Biochemistry and DPhil in Biological Sciences from Oxford University.